NEW HAVEN, Conn., Dec. 12, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting migraine and neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 3,355,705 of its common shares at a price to the public of $37.25 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 503,355 common shares at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be $125 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Biohaven. The offering is expected to close on December 17, 2018, subject to customary closing conditions.
Goldman Sachs & Co. LLC and Piper Jaffray & Co. are acting as joint book-running managers of the offering. Morgan Stanley and Cantor Fitzgerald & Co. are acting as bookrunners. William Blair is acting as co-manager.
The offering is being made only by means of a prospectus. When available, copies of the final prospectus related to the offering may be obtained from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected]; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at [email protected].
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Dr. Vlad Coric Chief Executive Officer Biohaven Pharmaceutical Holding Company Ltd. Phone: (203) 404-0410 Email: [email protected]
SOURCE Biohaven Pharmaceutical Holding Company Ltd.